SEARCH

SEARCH BY CITATION

References

  • Arndt CF, Salle M, Derambure PH, Deefort-Dhellemmes S, Hache JC. (2002) The effect on vision of associated treatment in patients taking vigabatrin: carbamazepine versus valporate. Epilepsia 43:812817.
  • Bruni J, Guberman A, Vachon L, Desforges C. (2000) Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. Seizure 9:224232.
  • Chadwick D. (1999) Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Lancet 354:1319.
  • Cubbidge RP. (2005) In DoshiS, HarveyW (Eds) Visual Fields, Elsevier Butterworth Heinemann Ltd. London , U.K.
  • Curcio CA, Sloan KR, Kalina RE, Hendrickson AE. (1990) Human photoreceptor topography. J Comp Neurol 292:497523.
  • Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon A. (1999) Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 106:17921798.
  • Electronic Medicines Compendium. (2006). http://emc.medicines.org.uk/.
  • Frisén L, Malmgren K. (2003) Characterization of vigabatrin-associated optic atrophy. Acta Ophthalmol Scand 81:466473.
  • Frisén L. (2004) Vigabatrin-associated loss of vision: rarebit perimetry illuminates the dose-damage relationship. Acta Ophthalmol Scand 82:5458.
  • Gerasimov MR, Schiffer WK, Brodie JD, Lennon IC, Taylor SJC, Dewey SL. (2000) [gamma]-Aminobutyric acid mimetic drugs differentially inhibit the dopaminergic response to cocaine. Eur J Pharmacol 395:129135.
  • Guberman A, Bruni J. (2000) Long-term open multicentre, add-on trial of vigabatrin in adult resistant partial epilepsy. Seizure 9:112118.
  • Guerrini R. (2006) Epilepsy in children. Lancet 367:499524.
  • Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TTJM, Van Veelen CWM. (2000) Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 41:581587.
  • Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TTJM, Stilma JS. (2001) Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 42:262267.
  • Hosking SL, Roff Hilton EJ, Embleton SJ, Gupta AK. (2003) Epilepsy patients treated with vigabatrin exhibit reduced ocular blood flow. Br J Ophthalmol 87:96100.
  • Hudson C, Wild JM, O'Neill EC. (1994) Fatigue effects during a single session of automated static threshold perimetry. Invest Ophthalmol Vis Sci 35:26880.
  • Jonas JB, Schneider U, Naumann GO. (1992) Count and density of human retinal photoreceptors. Graefes Arch Clin Exp Ophthalmol 230:505510.
  • Kalviainen R, Nousiainen I, Mantyarvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P. (1999) Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 53:922926.
  • Kinirons P, Cavalleri GL, O'Rourke D, Doherty CP, Reid I, Logan P, Liggan B, Delanty N. (2006) Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 47:311317.
  • Lawden MC, Eke T, Degg C, Harding GFA, Wild JM. (1999) Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 67:716722.
  • Lynn JR. (1969) Examination of the visual field in glaucoma. Invest Ophthalmol Vis Sci 8:7684.
  • Malmgrem K, Ben-Menachem E, Frisén L. (2001) Vigabatrin visual toxicity; evoloution and dose dependence. Epilepsia 42:609615.
  • Manucheri K, Goodman S, Siviter L, Nightingale S. (2000) A controlled study of vigabatrin and visual field abnormalities. Br J Ophthalmol 84:499505.
  • Newman WD, Tocher K, Acheson JF. (2002) Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye 16:567571.
  • Nicolson A, Leach JP, Chadwick DW, Smith DF. (2002) The legacy of vigabatrin in a regional epilepsy clinic. J Neurol Neurosurg Psychiatry 73:327329.
  • Nousiainen I, Mantyjarvi M, Kalviainen R. (2001) No reversion in vigabatrin-associated visual field defects. Neurology 57:19161917.
  • Ravindran J, Blumbergs P, Crompton J, Pietris G, Waddy H. (2001) Visual field loss associated with vigabatrin: pathological correlations. J Neurol Neurosurg Psychiatry 132:809.
  • Roff Hilton EJ, Cubbidge RP, Betts T, Comaish IF, Hosking SL. (2002) Epilepsy patients treated with vigabatrin exhibit central visual function deficits. Epilepsia 43:13511359.
  • Russell-Eggitt IM, Mackey DA, Taylor DSI, Timms C, Walker JW. (2000) Vigabatrin associated visual field defects in children. Eye 14:334339.
  • Sanabria O, Feuer WJ, Anderson DR. (1991) Pseudo-loss of fixation in automated perimetry. Ophthalmology 98:7678.
  • Schiffer WK, Gerasimov MR, Bermel RA, Brodie JD, Dewey SL. (2000) Stereoselective inhibition of dopaminergic activity by gamma vinyl-GABA following a nicotine or cocaine challenge: a pet/microdialysis study. Life Sciences 66:L169L173.
  • Schiffer WK, Marsteller D, Dewey SL. (2003) Sub-chronic low dose gamma-vinyl GABA (vigabatrin) inhibits cocaine-induced increases in nucleus accumbens dopamine. Psychopharmacologia 168:339343.
  • Toggweiler S, Wieser HG. (2001) Concentric visual field restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 10:420423.
  • Trope GE, Britton R. (1987) A comparison of Goldmann and Humphrey automated perimetry in patients with glaucoma. Br J Ophthalmol 71:489493.
  • Versino M, Veggiotti P. (1999) Reversibility of vigabatrin-induced visual-field defect. Lancet 354:486.
  • Wild JM, Martinez C, Reinshagenn G, Harding GFA. (1999) Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 40:17841794.
  • Wood JM, Wild JM, Hussey MK, Crews SJ. (1987) Serial examination of the normal visual field using Octopus automated projectionperimetry: evidence for a learning effect. Acta Ophthalmol (Copenh) 65:32633.